TScan Therapeutics, Inc.’s TCRX share price has dipped by 5.81%, which has investors questioning if this is right time to buy ...

Novartis, meanwhile, is also in the throes of a cash-conserving drive that it now says could slash $1.5 billion off its costs by 2024, up from its earlier estimate of $1 billion, that will see ...

Based in Basel, Granite Bio has emerged from stealth with a focus on developing first-in-class antibodies targeting multiple autoimmune diseases. The company has secured $100 million in two funding ...

Explore opportunities with Novartis below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.